Clinical perspectives of PARP inhibitors

Pharmacological Research

Volumn 52, Issue 1 SPEC. ISS., 2005, Pages 109-118

  Graziani, Grazia ^a   Szabó, Csaba ^b,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b INOTEK CORPORATION   (United States)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

Cancer; Clinical trials; Development; Heart; Inhibitors; Poly(ADP ribose) polymerase; Reperfusion; Stroke

Indexed keywords

3 AMINOBENZAMIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; AG 14361; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CEP 6800; DACARBAZINE; DEXAMETHASONE; GPI 15427; GPI 6150; INO 1001; IRINOTECAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG;

BRAIN LYMPHOMA; BRAIN METASTASIS; CANCER PATIENT; CARCINOGENICITY; CARDIOPULMONARY BYPASS; CARDIOTOXICITY; CELL DEATH; CENTRAL NERVOUS SYSTEM METASTASIS; COLON CANCER; DIABETES MELLITUS; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; GENOTOXICITY; GLIOMA; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; MELANOMA; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; OLIGODENDROGLIOMA; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; SOLID TUMOR; STROKE; TERATOGENICITY; TREATMENT FAILURE;

EID: 19444362951     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phrs.2005.02.013     Document Type: Article

References (52)

1. L. Virag, and C. Szabo The therapeutic potential of poly(ADP-ribose) polymerase inhibitors Pharmacol Rev 54 2002 375 429
2. V.G. Nicoletti, and A.M. Stella Role of PARP under stress conditions: cell death or protection? Neurochem Res 28 2003 187 194
3. S. Beneke, J. Diefenbach, and A. Burkle Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions Int J Cancer 111 2004 813 818
4. Z. Herceg, and Z.Q. Wang Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death Mutat Res 477 2001 97 110
5. P.A. Nguewa, M.A. Fuertes, B. Valladares, C. Alonso, and J.M. Perez Poly(ADP-Ribose) Polymerases: Homology, Structural Domains and Functions. Novel Therapeutical Applications Prog Biophys Mol Biol 88 2005 143 172
6. Z. Herceg, and Z.Q. Wang Failure of poly(ADP-ribose) polymerase cleavage by caspases leads to induction of necrosis and enhanced apoptosis Mol Cell Biol 19 1999 5124 5133
7. M. Leist, B. Single, G. Kunstle, C. Volbracht, H. Hentze, and P. Nicotera Apoptosis in the absence of poly-(ADP-ribose) polymerase Biochem Biophys Res Commun 233 1997 518 522
8. Z.Q. Wang, L. Stingl, C. Morrison, M. Jantsch, M. Los, and K. Schulze-Osthoff PARP is important for genomic stability but dispensable in apoptosis Genes Dev 11 1997 2347 2358
9. L. Virag, A.L. Salzman, and C. Szabo Poly(ADP-ribose) synthetase activation mediates mitochondrial injury during oxidant-induced cell death J Immunol 161 1998 3753 3759
10. B. Heller, Z.Q. Wang, E.F. Wagner, J. Radons, A. Burkle, and K. Fehsel Inactivation of the poly(ADP-ribose) polymerase gene affects oxygen radical and nitric oxide toxicity in islet cells J Biol Chem 270 1995 11176 11180
11. C. Szabo, L. Virag, S. Cuzzocrea, G.S. Scott, P. Hake, and M.P. O'Connor Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase Proc Natl Acad Sci USA 95 1998 3867 3872
12. M.J. Eliasson, K. Sampei, A.S. Mandir, P.D. Hurn, R.J. Traystman, and J. Bao Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia Nat Med 3 1997 1089 1095
13. H.C. Ha, and S.H. Snyder Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion Proc Natl Acad Sci USA 96 1999 13978 13982
14. F.G. Soriano, P. Pacher, J. Mabley, L. Liaudet, and C. Szabo Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase Circ Res 89 2001 684 691
15. H.B. Jijon, T. Churchill, D. Malfair, A. Wessler, L.D. Jewell, and H.G. Parsons Inhibition of poly(ADP-ribose) polymerase attenuates inflammation in a model of chronic colitis Am J Physiol Gastrointest Liver Physiol 279 2000 G641 G651
16. L. Tentori, and G Graziani Chemopotentiation by PARP inhibitors in cancer therapy Pharmacol Res 52 2005 25 33
17. L. Tentori, I. Portarena, and G. Graziani Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors Pharmacol Res 45 2002 73 85
18. L. Tentori, and G. Graziani Temozolomide: an update on pharmacological strategie sto increase its antitumor activity Med Chem Rev-Online 1 2004 144 150
19. E.S. Newlands, M.F. Stevens, S.R. Wedge, R.T. Wheelhouse, and C. Brock Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials Cancer Treat Rev 23 1997 35 61
20. V. Schreiber, J.-C. Amé, P. Dollé, I. Schultz, B. Rinaldi, and V. Fraulob Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1 J Biol Chem 277 2002 23028 23036
21. L. Tentori, C. Leonetti, M. Scarsella, G. d'Amati, I. Portarena, and G. Zupi Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematological malignancy at the CNS site Blood 99 2002 2241 2244
22. L. Tentori, C. Leonetti, M. Scarsella, G. D'Amati, M. Vergati, and I. Portarena Systemic administration of GPI 15427 a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma Clin Cancer Res 9 2003 5370 5379
23. C.R. Calabrese, R. Almassy, S. Barton, M.A. Batey, A.H. Calvert, and S. Canan-Koch Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG 14361 J Natl Cancer Inst 96 2004 56 67
24. Curtin N., PARP-1: A new target for cancer treatment, Cancer Research UK Scientific YearBook, 2003. 2002-2003:52-54.
25. S.J. Miknyoczki, S. Jones-Bolin, S. Pritchard, K. Hunter, H. Zhao, and W. Wan Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor Mol Cancer Ther 2 2003 371 382
26. L. Tentori, C. Leonetti, M. Scarsella, M. Vergati, W. Xu, and D. Calvin Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors Int J Oncol 26 2005 415 424
27. T.M. Yung, S. Sato, and M.S. Satoh Poly(ADP-ribosyl)ation as a DNA damage-induced post-translational modification regulating poly(ADP-ribose) polymerase-1 topoisomerase I interaction J Biol Chem 279 2004 39686 39696
28. M. Malanga, and F.R. Althaus Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and induces DNA strand break resealing J Biol Chem 279 2004 5244 5248
29. S. Boulton, S. Kyle, and Durkacz Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage Carcinogenesis 20 1999 199 203
30. S.J. Veuger, N.J. Curtin, G.C.M. Smith, and B.W. Durkacz Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair Oncogene 23 2004 7322 7329
31. S. Galande, and T. Kohwi-Shigematsu Poly(ADP-ribose) polymerase and Ku autoantigen form a complex and synergistically bind to matrix attachment sequences J Biol Chem 274 1999 20521 20528
32. M. Audebert, B. Salles, and P. Calsou Involvement of Poly(ADP-ribose) Polymerase-1 and XRCC1/DNA Ligase III in an Alternative Route for DNA Double-strand Breaks Rejoining J Biol Chem 279 2004 55117 55126
33. W.A. Brock, L. Milas, S. Bergh, R. Lo, C. Szabo, and K.A. Mason Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase Cancer Lett 205 2004 155 160
34. L. Tentori, I. Portarena, E. Bonmassar, and G. Graziani Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells Cell Death Differ 8 2001 457 469
35. J.M. de Murcia, C. Niedergang, C. Trucco, M. Ricoul, B. Dutrillaux, and M. Mark Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells Proc Natl Acad Sci USA 94 1997 7303 7307
36. W.M. Tong, U. Cortes, and Z.Q. Wang Poly(ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis Biochim Biophys Acta 1552 2001 27 37
37. A. Shibata, N. Kamada, K.I. Masumura, T. Nohmi, S. Kobayashi, H. Teraoka, H. Nakagama, T. Sugimura, H. Suzuki, and M. Masutani Parp-1 deficiency causes an increase of deletion mutations and insertions/rearrangements in vivo after treatment with an alkylating agent Oncogene 24 2005 1328 1337
38. M. Masutani, H. Nakagama, and T. Sugimura Poly(ADP-ribose) and carcinogenesis Genes Chromosom. Cancer 38 2003 339 348
39. L. Tentori, I. Portarena, P. Vernole, B. Gold, and G. Graziani Apoptotic and cytotoxic effects of a methyl sulfonate ester that selectively generates N-3-methyladenine and poly (ADP-ribose) polymerase inhibitors in normal peripheral blood lymphocytes Cancer Chemother Pharmacol 49 2002 217 224
40. C.M. Simbulan-Rosenthal, D.S. Rosenthal, R. Luo, J.H. Li, J. Zhang, and M.E. Smulson Inhibition of poly(ADP-ribose) polymerase activity is insufficient to induce tetraploidy Nucl Acids Res 29 2001 841 849
41. F. Dantzer, H.P. Nasheuer, J.L. Vonesch, G. de Murcia, and J. Menissier-de Murcia Functional association of poly(ADP-ribose) polymerase with DNA polymerase alpha-primase complex: a link between DNA strand break detection and DNA replication Nucl Acids Res 26 1998 1891 1898
42. M. Masson, C. Niedergang, V. Schreiber, S. Muller, J. Menissier-de Murcia, and G. de Murcia XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage Mol Cell Biol 18 1998 3563 3571
43. C.M. Simbulan-Rosenthal, D.H. Ly, D.S. Rosenthal, G. Konopka, R. Luo, and Z.Q. Wang Misregulation of gene expression in primary fibroblasts lacking poly(ADP-ribose) polymerase Proc Natl Acad Sci USA 97 2000 11274 11279
44. A. Huber, P. Bai, J.M. de Murcia, and G. de Murcia PARP-1, PARP-2 and ATM in the DNA damage response: functional synergy in mouse development DNA Repair (Amst) 3 2004 1103 1108
45. W.M. Tong, H. Ohgaki, H. Huang, C. Granier, P. Kleihues, and Z.Q. Wang Null mutation of DNA strand break-binding molecule poly(ADP-ribose) polymerase causes medulloblastomas in p53(-/-) mice Am J Pathol 162 2003 343 352
46. T. Nozaki, H. Fujihara, M. Watanabe, M. Tsutsumi, K. Nakamoto, and O. Kusuoka Parp-1 deficiency implicated in colon and liver tumorigenesis induced by azoxymethane Cancer Sci 94 2003 497 500
47. C. Conde, M. Mark, F.J. Oliver, A. Huber, G. de Murcia, and J. Menissier-de Murcia Loss of poly(ADP-ribose) polymerase-1 causes increased tumour latency in p53-deficient mice EMBO J 20 2001 3535 3543
48. M.A. Hans, M. Muller, M. Meyer-Ficca, A. Burkle, and J.H. Kupper Overexpression of dominant negative PARP interferes with tumor formation of HeLa cells in nude mice: evidence for increased tumor cell apoptosis in vivo Oncogene 18 1999 7010 7015
49. D. Martin-Oliva, F. O'Valle, J.A. Munoz-Gamez, M.T. Valenzuela, M.I. Nunez, and M. Aguilar Crosstalk between PARP-1 and NF-kappaB modulates the promotion of skin neoplasia Oncogene 23 2004 5275 5283
50. J.B. Pillai, H.M. Russell, J.S. Raman, V. Jeevanandam, and M.P. Gupta Increased Expression of Poly (ADP) Ribose Polymerase-1 Contributes to Caspase-Independent Myocyte Cell Death during Heart Failure Am J Physiol Heart Circ Physiol 288 2005 H486 H496
51. C. Szabo, P. Pacher, Z. Zsengeller, A. Vaslin, K. Komjati, and R. Benko Angiotensin II-mediated endothelial dysfunction: role of poly(ADP-ribose) polymerase activation Mol Med 10 2004 28 35
52. S. Cuzzocrea, R. Di Paola, E. Mazzon, T. Genovese, C. Muia, and A.P. Caputi WY 14643 a potent exogenous PPAR-alpha ligand, reduces intestinal injury associated with splanchnic artery occlusion shock Shock 22 2004 340 346